NFlection Therapeutics

N Flection Therapeutics

Biotechnology, 714 Woodcrest Rd, Boston, Massachusetts, 19087, United States, 11-50 Employees

nflectionrx.com

  • facebook
  • LinkedIn

phone no Phone Number: 61********

Who is NFLECTION THERAPEUTICS

NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous ...

Read More

map
  • 714 Woodcrest Rd, Boston, Massachusetts, 19087, United States Headquarters: 714 Woodcrest Rd, Boston, Massachusetts, 19087, United States
  • 2014 Date Founded: 2014
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from NFLECTION THERAPEUTICS

NFlection Therapeutics Org Chart and Mapping

Employees

Chris Omara

Director Clinical Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding NFlection Therapeutics

Answer: NFlection Therapeutics's headquarters are located at 714 Woodcrest Rd, Boston, Massachusetts, 19087, United States

Answer: NFlection Therapeutics's phone number is 61********

Answer: NFlection Therapeutics's official website is https://nflectionrx.com

Answer: NFlection Therapeutics's revenue is $1 Million to $5 Million

Answer: NFlection Therapeutics's SIC: 2836

Answer: NFlection Therapeutics's NAICS: 541714

Answer: NFlection Therapeutics has 11-50 employees

Answer: NFlection Therapeutics is in Biotechnology

Answer: NFlection Therapeutics contact info: Phone number: 61******** Website: https://nflectionrx.com

Answer: NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi. To address these RAS-mediated disorders, driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, we are developing first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access